Eficacia de las células estromales mesenquimales (MSC) como tratamiento para pacientes con enfermedad obstructiva crónica (EPOC): Revisión Sistemática
DOI:
https://doi.org/10.26820/recimundo/7.(1).enero.2023.654-663Keywords:
Células Madre Mesenquimales, Enfermedad Pulmonar Obstructiva Crónica, Terapia BiológicaAbstract
Objetivo: Determinar la eficacia del tratamiento con células estromales mesenquimales (MSC), en pacientes con enfermedad pulmonar obstructiva crónica (EPOC). Materiales y métodos: Análisis descriptivo, corte transversal, orientado hacia una revisión sistemática de artículos en inglés, publicados durante los últimos 6 años, en bases de datos como: PubMed, ScienceDirect, ClinicalTrials.gov; a través del uso de descriptores (DeCS) y operadores booleanos como: “Mesenchymal Stromal Cells¨ AND ¨Therapy¨ AND ¨COPD¨. Resultados: Se determinó que las MSC son prometedoras para aplicaciones terapéuticas en EPOC, dada la facilidad para obtenerlas, su escasa inmunogenicidad, sus propiedades reparadoras tisulares e inmunomodulación. Conclusiones: El éxito de esta terapia a las semanas o meses de la terapia con MSC, van a depender de la fase de la enfermedad, la presencia de exacerbaciones y factores de riesgo asociados a cada paciente.Downloads
References
Coppolino I, Ruggeri P, Nucera F, Cannavò MF, Adcock I, Girbino G, et al. Role of Stem Cells in the Pathogenesis of Chronic Obstructive Pulmonary Disease and Pulmonary Emphysema. COPD 2018;15(5):536–56. https://doi.org/10.1080/15412555.2018.1536116
Mohammadipoor A, Antebi B, Batchinsky AI, Cancio LC. Therapeutic potential of products derived from mesenchymal stem/stromal cells in pulmonary disease. Respir Res 2018;19(1):1–14.https://doi.org/10.1186/s12931-018-0921-x
Glassberg MK, Csete I, Simonet E, Elliot SJ. Stem Cell Therapy for COPD: Hope and Exploitation. Chest 2021;160(4):1271–81. https://doi.org/10.1016/j.chest.2021.04.020
Squassoni SD, Sekiya EJ, Fiss E, Lapa MS, Cayetano DDS, Nascimento F, et al. Autologous Infusion of Bone Marrow and Mesenchymal Stromal Cells in Patients with Chronic Obstructive Pulmonary Disease: Phase I Randomized Clinical Trial. Int J COPD 2021;16(August):3561-74.https://doi.org/10.2147/COPD.S332613
Cruz FF, Rocco PRM. The potential of mesenchymal stem cell therapy for chronic lung disease. Expert Rev Respir Med 2020;14(1):31–9. https://doi.org/10.1080/17476348.2020.1679628
DeCS Server - Main Menu [Internet].https://decs2020.bvsalud.org/cgibin/wxis1660.exe/decsserver/?IsisScript=../cgibin/decsserver/decsserver.xis&interface_language=e&previous_page=homepage&previous_task=NULL&task=start
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. Declaración PRISMA 2020: una guía actualizada para la publicación de revisiones sistemáticas. Rev Española Cardiol 2021;74(9):790–9. http://www.revespcardiol.org/es-declaracion-prisma-2020-una-guia-articulo S0300893221002748
Scimago Journal & Country Rank [Internet]. Disponible en: https://www.scimagojr.com/
Calzetta L, Aiello M, Frizzelli A, Camardelli F, Cazzola M, Rogliani P, et al. Stem Cell-Based Regenerative Therapy and Derived Products in COPD: A Systematic Review and Meta-Analysis. Cells 2022;11(11):1–20.https://doi.org/10.3390/cells11111797
Meridigen Biotech. Mesenchymal Stem Cells for The Treatment of Chronic Obstructive Pulmonary Disease - Full Text View - ClinicalTrials.gov 2022. https://clinicaltrials.gov/ct2/show/NCT04206007
De Oliveira HG, Cruz FF, Antunes MA, De Macedo Neto AV, Oliveira GA, Svartman FM, et al. Combined bone marrow-derived mesenchymal stromal cell therapy and one-way endobronchial valve placement in patients with pulmonary emphysema: A phase i clinical trial. Stem Cells Transl Med 2017;6(3):962–9. https://doi.org/10.1002/sctm.16-0315
Le Thi Bich. P; Thi. H; Ngo. H; Van. T; Khac. H; Van. D; et Al. Allogeneic umbilical cord-derived mesenchymal stem cell transplantation for treating chronic obstructive pulmonary disease: a pilot clinical study. Stem Cell Res Ther 2020;11(1):1–14. https://doi.org/10.1186/s13287-020-1583-4
Armitage JD, Tan DBA, Sturm M, Moodley YP. Transcriptional profiling of circulating mononuclear cells from patients with chronic obstructive pulmonary disease receiving mesenchymal stromal cell infusions. Stem Cells Transl Med 2021;10(11):1470-81. https://doi.org/10.1002/sctm.21-0024
Weiss DJ, Segal K, Casaburi R, Hayes J, Tashkin D. Effect of mesenchymal stromal cell infusions on lung function in COPD patients with high CRP levels. Respir Res 2021;22(1):1-11.https://doi.org/10.1186/s12931-021-01734-8
Stolk J, Broekman W, Mauad T, Zwaginga JJ, Roelofs H, Fibbe WE, et al. A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema. QJM An Int J Med 2016;109(5):331-6. https://academic.oup.com/qjmed/article/109/5/331/1752925
Karaoz. E, Kalemci. S EF. Improving effects of mesenchymal stem cells on symptoms of chronic obstructive pulmonary disease. Bratisl Med J 2020;121(3):188–91. https://pubmed.ncbi.nlm.nih.gov/32115975/
Hoang DM, Nguyen KT, Nguyen AH, Nguyen BN, Nguyen LT. Allogeneic human umbilical cord-derived mesenchymal stem/stromal cells for chronic obstructive pulmonary disease (COPD): study protocol for a matched case-control, phase I/II trial. BMJ Open 2021;11(5). https://pubmed.ncbi.nlm.nih.gov/33986057/
Abbaszadeh H, Ghorbani F, Abbaspour-Aghdam S, Kamrani A, Valizadeh H, Nadiri M, et al. Chronic obstructive pulmonary disease and asthma: mesenchymal stem cells and their extracellular vesicles as potential therapeutic tools. Stem Cell Res Ther 2022;13(1):1-15. https://stemcellres.biomedcentral.com/articles/10.1186/s13287-022-02938-5
Sun Z, Li F, Zhou X, Chung KF, Wang W, Wang J. Stem cell therapies for chronic obstructive pulmonary disease: Current status of pre-clinical studies and clinical trials. J Thorac Dis 2018;10(2):1084–98. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5864644/
Chen X, Wang F, Huang Z, Wu Y, Geng J, Wang Y. Clinical applications of mesenchymal stromal cell-based therapies for pulmonary diseases: An update and concise review. Int J Med Sci 2021;18(13):2849-70. https://doi.org/10.7150%2Fijms.59218
